Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

C3PO, 2020 NCT04355767

convalescent plasma treatment (n=257) vs. placebo (n=254)

randomized controlled trial   some concerns about risk of bias

Studied treatment

COVID-19 convalescent plasma
One unit (250 mL) of ABO-compatible COVID-19 convalescent plasma.

Control treatment

Placebo
250 mL of normal saline (colored with a parenteral multivitamin concentrate to resemble plasma).

Patients

COVID 19 outpatients

=< 18 years with one or more symptoms of COVID-19 illness and laboratory-confirmed SARS-Cov-2 infection, at least one study defined risk factor for severe COVID-19 illness, clinical team deems stable for outpatient management without supplemental oxygen, CP available at the site at the time of enrollment, duration of symptoms =< 7 days at ED presentation, informed consent from subject.

Method

Single-blind.

Multicenter: 48 hospital emergency departments across the United States.

Remark

Trial enrollment was halted after the second planned interim analysis of the primary outcome indicated that the a priori stopping threshold for futility had been reached on the basis of a posterior predictive probability of success of 0.042.

CONV-ERT, 2021 NCT04621123

convalescent plasma treatment (n=188) vs. placebo (n=160)

randomized controlled trial   low risk of bias

Studied treatment

convalescent plasma
anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml

Control treatment

placebo
200 to 300ml of sterile saline solution 0.9%.

Patients

COVID 19 outpatients

Method

double blind

4 centers, Spain

Remark

The trial was stopped early following a data safety monitoring board recommendation because more than 85% of the target population had received a COVID-19 vaccin

CoV-Early (Gharbharan), 2022 NCT04589949

convalescent plasma treatment (n=207) vs. placebo (n=209)

randomized controlled trial   low risk of bias

Studied treatment

convalescent plasma

Control treatment

placebo
regular plasma

Patients

COVID 19 outpatients

Method

double blind

netherlands

Remark

phase 3. Based on the recommendation by the DSMB (rapid uptake of vaccination and effective monoclonal antibodies available for high risk outpatients), the study was terminated on the 13th of July 2021 before the planned sample size of 690 was reached